Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | HCK | P08631 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618981 | 0.75 | CYP2A6 (0.41) | EGFR | |
| SCHEMBL31065825 | 0.75 | EGFR (0.41) | EGFRPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL23178627 | 0.74 | EGFR (0.31) | EGFR | |
| SCHEMBL13452501 | 0.73 | CCR1 (0.52) | MTOR | |
| SCHEMBL10058347 | 0.73 | CCR1 (0.34) | — | |
| SCHEMBL18779069 | 0.73 | CCR1 (0.57) | — | |
| SCHEMBL14134266 | 0.72 | LMNA (0.40) | KDR | |
| SCHEMBL18791475 | 0.71 | PAK4 (0.37) | — | |
| SCHEMBL18791200 | 0.71 | CCR1 (0.33) | — | |
| SCHEMBL29439760 | 0.71 | EGFR (0.38) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-01-26 | — | — | US | disclosed |
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-10851113-B2 | Heterocyclic inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190330228-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-10-31 | — | — | US | disclosed |
| US-20190282582-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-09-19 | — | — | US | disclosed |
| US-10328078-B2 | Pteridine dione monocarboxylate transporter inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-25 | — | — | US | disclosed |
| US-9994555-B2 | Chromenone inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994555-B2 | Chromenone inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-06-12 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180008605-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-01-11 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7893059-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7846929-B2 | Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents | GENENTECH, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | EGFR 2057/4885PIK3CD 10/4885ABL1 401/4885 |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | EGFR 1332/4885PIK3CD 2/4885ABL1 312/4885 |
| US-20190282582-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | SLC16A1, SLC16A3, SLC16A7 | EGFR 2486/4885PIK3CD 1908/4885ABL1 4442/4885 |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | EGFR 3873/4885PIK3CD 2/4885ABL1 986/4885 |
| US-10851113-B2 | Heterocyclic inhibitors of monocarboxylate transporters | SLC16A1, SLC16A3, SLC16A7 | EGFR 1210/4885PIK3CD 1527/4885ABL1 3779/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | EGFR 1119/4885PIK3CD 5/4885ABL1 581/4885 |
| US-20180008605-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | SLC16A1, SLC16A3, SLC16A7 | EGFR 2486/4885PIK3CD 1908/4885ABL1 4442/4885 |
| US-20210094969-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | EGFR 1141/4885PIK3CD 1590/4885ABL1 3916/4885 |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PI4KB, PI4KA | EGFR 2158/4885PIK3CD 11/4885ABL1 419/4885 |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | EGFR 3093/4885PIK3CD 2/4885ABL1 700/4885 |
| US-20190330228-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | EGFR 1339/4885PIK3CD 1660/4885ABL1 3790/4885 |
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | EGFR 3041/4885PIK3CD 1732/4885ABL1 2341/4885 |
| US-10328078-B2 | Pteridine dione monocarboxylate transporter inhibitors | SLC16A1, SLC16A3, SLC16A7 | EGFR 2486/4885PIK3CD 1908/4885ABL1 4442/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | EGFR 2049/4885PIK3CD 2/4885ABL1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.